<DOC>
	<DOCNO>NCT00704600</DOCNO>
	<brief_summary>The aim study safety activity nelfinavir , add standard chemoradiotherapy patient locally advanced rectal cancer . Furthermore analysis effect nelfinavir combine chemoradiation tumour tissue study</brief_summary>
	<brief_title>Nelfinavir , Phase I/Phase II Rectal Cancer Study</brief_title>
	<detailed_description>Objective study : The aim study safety activity nelfinavir , add standard chemoradiotherapy ( 28x1.8 Gy capecitabine 825 mg/m2 BID ) patient locally advanced rectal cancer . Furthermore analysis effect nelfinavir combine chemoradiation tumor tissue study . Study design : This open label , single-center phase I/II trial . During phase I toxicity 2 dose level study ( 750 mg BID 1250 mg BID ) . During phase II activity nelfinavir combination capecitabine radiotherapy study , use MTD phase I . With respect translational research , phosphorylation Akt monocytes tumorcells measure different timepoints treatment . Furthermore , dynamic CT-PET scan obtain different time point get impression change SUV perfusion treatment correlate change pathological response . Study population : Patients locally advanced rectal cancer , candidate chemoradiotherapy . In phase I , 6 patient include . In case occurrence dose limit toxicity , extra patient include , accord rule describe protocol . In phase II , 55 patient include .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Histologically proven adenocarcinoma rectum ( tumor &lt; 15cm anal verge ) Age &gt; = 18 year UICC T34 N02 M0 WHO performance status 02 Less 10 % weight loss last 6 month No recent ( &lt; 3 month ) severe cardiac disease ( arrhythmia , congestive heart failure , infarction ) Serum bilirubin = &lt; 3x normal ASAT ALAT = &lt; 2,5x normal Creatinin clearance &gt; 50 ml/min Willing able comply study prescriptions No history prior pelvic radiotherapy No known HIV infection No hemophilia No concurrent medication metabolize CYP3A4 isoenzyme ( calcium channel blocker , antifungal agent , macrolide antibiotic , gastrointestinal prokinetics , terfenadin , midazolam ) Statins stop ( except pravastatin fluvastatin ) , No concurrent use St. John 's Wort ( Hypericum perforatum ) Women pregnant lactate Being willing able undergo one extra biopsy Have give write informed consent patient registration opposite</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Locally advanced rectal cancer</keyword>
	<keyword>nelfinavir</keyword>
	<keyword>radiosensitivity</keyword>
	<keyword>chemoradiation</keyword>
</DOC>